Applications of Axitinib in Industrial Manufacturing

Axitinib is a high-purity pharmaceutical intermediate essential for the production of targeted anticancer agents. Our facility supplies Axitinib to regulated sectors that demand precise control over synthesis and formulation. The following genuine application scenarios represent the primary downstream usage channels supported by our manufacturing expertise.

1. Oncology Finished Dosage Form Manufacturing

Axitinib serves as the anchor molecule in the synthesis of advanced oral formulations for kidney cancer therapies. Global oncology drug producers integrate our Axitinib into GMP-controlled blending, granulation, and tabletting lines. The compound’s stability profile supports direct incorporation after pre-milling and sifting, with critical QC checkpoints for impurity control before film coating and packaging. We work closely with formulation chemists to match delivered particle size distribution and optimize flow properties in high-speed tablet presses and capsule filling machines.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA cGMP regulations (21 CFR Parts 210/211)
• EU EudraLex Vol 4 GMP compliance
• Chinese Pharmacopoeia and USP monographs (identity, purity, residual solvents)

Typical usage ratio

• Active content is 1–8 mg per tablet or capsule, with blend ratios determined by the target strength (subject to process validation based on formulation and batch size)

Downstream process integration

• Feeds directly into premix or direct compression step after verification of compliance and release testing
• Final blending with excipients (e.g., microcrystalline cellulose, lactose)
• Downstream steps include granulation, compression, and film-coating (if required)
• Packaged as finished tablets or capsules for clinical supply or commercial distribution

Final product types

• Oral solid dosage forms (tablets, capsules)
• Blister-packed and HDPE-bottled oncology pharmaceuticals

2. Clinical Research and Development (R&D) Synthesis

Specialty formulation developers and CROs use Axitinib in new drug development programs for preclinical and clinical trials. Small-scale GMP suites require highly characterized Axitinib for inclusion in proto-formulations and compatibility studies. Lead time and batch-to-batch consistency are critical to accelerate R&D cycles, with our manufacturing providing full traceability and flexible pack sizes for lab-scale and pilot batch manufacture.

Industry compliance standards

• ICH Q11: Development and Manufacture of Drug Substances
• FDA IND (Investigational New Drug) and EU Clinical Trial Application requirements
• GLP (Good Laboratory Practice) for nonclinical R&D use
• Analytical method validation according to USP and Ph. Eur.

Typical usage ratio

• 1–10 mg per dose unit in early R&D and up to several grams per batch for pilot formulations (adjusted by trial protocol and phase requirements)

Downstream process integration

• Introduced into formulation screening, salt selection, and stability studies
• Used in compatibility and toxicity studies throughout R&D phases
• Scaled from analytical lab blending to technical transfer for pilot batch production

Final product types

• Formulation prototypes for Phase I–III clinical trials
• Reference standards for bioanalytical and dissolution testing

3. High-Purity Reference Standard Production

Pharmaceutical QC laboratories and reference material providers procure Axitinib as a certified reference standard. Stringent impurity profiling and assay validation underpin its use for analytical calibration and regulatory submissions. We support reference material lots with full documentation, including chromatographic purity, isomeric content, and uncertainty values as required by leading compendia.

Industry compliance standards

• ISO 17034: General requirements for the competence of reference material producers
• Pharmacopeial standards: USP, Ph. Eur., JP
• FDA and EMA guidelines for analytical reference standards in batch release

Typical usage ratio

• 5–50 mg per analytical batch as working standard; bulk reference standard supply as specified by laboratory protocol

Downstream process integration

• Direct weighing and solution preparation for assay, purity, and related substances analysis
• Preparation of linearity, accuracy, and precision validation batches
• Used in the qualification of analytical methods for regulatory filings

Final product types

• Certified reference materials for HPLC, GC, and LC-MS calibration
• QC release standards for in-process and finished product analysis

4. Specialty API Intermediate Supply for CDMO Integration

CDMO facilities integrate Axitinib as a key intermediate in the synthesis of proprietary or improved kinase inhibitors. Multi-step synthesis requires Axitinib of defined stereo- and regio-chemical purity, with validated impurity control supporting API registration dossiers. Custom packaging and logistics ensure direct transfer from our reactor vessel to filling isolators or reactors in closed-system operations, minimizing the risk of cross-contamination and environmental exposure.

Industry compliance standards

• ICH Q3A/B: Impurities in New Drug Substances and Products
• ISO 9001:2015 Quality Management Systems
• Custom supply agreements with defined containment and traceability protocols

Typical usage ratio

• Varies by synthetic route; typically 10–1000 g per API batch, with adjustments based on process yield and target batch size

Downstream process integration

• Direct charge to GMP reactor systems for next synthetic conversion steps (e.g. NMR characterization, salt formation, crystallization)
• Introduced after stage-specific in-process QC release and data transfer to CDMO partners
• Sterile transfer protocols for high-containment facilities

Final product types

• Crude API intermediates for further derivatization
• Final kinase inhibitor APIs, following additional chemical transformations